Kazia’s Paxalisib Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

Kazia Therapeutics Limited announced that its lead program, paxalisib, has been awarded Fast Track Designation by the FDA for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy.